Denghong Zhang

Denghong Zhang is a highly experienced scientist in the field of molecular biology and biochemistry, currently serving as a Principal Scientist at Bristol Myers Squibb since October 2021. Prior to this role, Zhang held similar positions at Aurion Biotech and CorneaGen, focusing on advancing DNA sequencing methodologies and diagnostics. Zhang's career also includes significant contributions at NanoString Technologies, Bionano Genomics, and UC San Diego, where research spanned from the application of mTOR inhibitors in cardiovascular diseases to the development of next-generation genome mapping technologies. Academically, Zhang earned a Ph.D. from the Shanghai Institute of Biochemistry and Cell Biology and has conducted postdoctoral research exploring cardiac function regulation.